ArticleJournal of clinical neurology (Seoul, Korea)2024
Impact of Apolipoprotein E ε4 in Alzheimer's Disease: A Meta-Analysis of Voxel-Based Morphometry Studies.
Article in Journal of clinical neurology (Seoul, Korea), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Sex-Specific Structural Vulnerability in Alzheimer's Disease: Insights from APOE ε 4-Negative Patients.Life (Basel, Switzerland) · 2026Article
- Altered Brain Functional Connectivity in Postherpetic Neuralgia and Its Association With Neuropathic Pain.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Review
- Review
- Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment.AIMS neuroscience · 2026Review
- Imaging markers of neuroinflammation in aging and Alzheimer's disease and related dementia: A comprehensive review.Neuroscience and biobehavioral reviews · 2025Review
- Current Clinical Applications of Structural MRI in Neurological Disorders.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Monoclonal Antibodies-A New Horizon in Alzheimer's Treatment.Journal of clinical neurology (Seoul, Korea) · 2025Article
- Kinematic correlates of early speech motor changes in cognitively intact APOE-ε4 carriers: a preliminary study using a color-word interference task.Frontiers in neurology · 2025Article
- Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics.Cells · 2024Review
- Tooth Loss in Periodontitis Patients-A Risk Factor for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2024Review
- Impact of Apolipoprotein E ε4 in Alzheimer's Disease: Insights From a Meta-Analysis.Journal of clinical neurology (Seoul, Korea) · 2024Article
- In 2024, theFrontiers in aging neuroscience · 2024Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
background and purposeAlzheimer's disease (AD) is the most-prevalent form of dementia and imposes substantial burdens at the personal and societal levels. The apolipoprotein E (APOE) ε4 allele is a genetic factor known to increase AD risk and exacerbate brain atrophy and its symptoms. We aimed to provide a comprehensive review of the impacts of APOE ε4 on brain atrophy in AD as well as in mild cognitive impairment (MCI) as a transitional stage of AD.
methodsWe performed a coordinate-based meta-analysis of voxel-based morphometry studies to compare gray-matter atrophy patterns between carriers and noncarriers of APOE ε4. We obtained coordinate-based structural magnetic resonance imaging data from 1,135 individuals who met our inclusion criteria among 12 studies reported in PubMed and Google Scholar.
resultsWe found that atrophy of the hippocampus and parahippocampus was significantly greater in APOE ε4 carriers than in noncarriers, especially among those with AD and MCI, while there was no significant atrophy in these regions in healthy controls who were also carriers.
conclusionsThe present meta-analysis has highlighted the significant link between the APOE ε4 allele and hippocampal atrophy in both AD and MCI, which emphasizes the critical influence of the allele on neurodegeneration, especially in the hippocampus. These findings improve the understanding of AD pathology, potentially facilitating progress in early detection, targeted interventions, and personalized care strategies for individuals at risk of AD who carry the APOE ε4 allele.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.